WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic (Elgazzar et al. preprint, Research Square, with editorial note) (2021)

Other · Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H (authors); Research Square (withdrawal) · July 14, 2021

Elgazzar A et al., 2021-07-14: The withdrawal record for the Egyptian Elgazzar preprint: Research Square marked it WITHDRAWN on 14 July 2021 over verifiable concerns, and the DOI resolves to a page headed WITHDRAWN.

Research Square withdrew this preprint on 14 July 2021 due to verifiable concerns communicated directly to our staff.

Elgazzar A et al., 2021-07-14: The withdrawal record for the Egyptian Elgazzar preprint: Research Square marked it WITHDRAWN on 14 July 2021 over verifiable concerns, and the DOI resolves to a page headed WITHDRAWN. Preprint withdrawal record (not a journal retraction). DOI 10.21203/rs.3.rs-100956/v4; the page title carries the prefix 'WITHDRAWN:' and the editorial note is dated 14 July 2021. Egypt (Zagazig University hospital). The preprint reported very large mortality reductions with ivermectin in 600 patients; those numbers fed the Bryant and Hill meta-analyses. The withdrawal notice gives no clinical detail. Recorded because C4 asks for the withdrawal as a document; the data-integrity and confounding critiques are IVE-45 (journal retraction of a meta-analysis built on it), IVE-49 (strongyloidiasis confounding) and IVE-50 (risk-of-bias). Study type: other.